Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Signaturefd LLC

Signaturefd LLC lifted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 15.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 352 shares of the medical research company’s stock after purchasing an additional 48 shares during the quarter. Signaturefd LLC’s holdings in Bio-Rad Laboratories were worth $114,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BIO. Brown Advisory Inc. increased its stake in shares of Bio-Rad Laboratories by 3.1% in the 3rd quarter. Brown Advisory Inc. now owns 955,732 shares of the medical research company’s stock worth $342,582,000 after acquiring an additional 28,724 shares during the last quarter. Earnest Partners LLC raised its stake in Bio-Rad Laboratories by 25.6% during the third quarter. Earnest Partners LLC now owns 351,510 shares of the medical research company’s stock worth $125,999,000 after purchasing an additional 71,570 shares during the period. Invesco Ltd. boosted its holdings in Bio-Rad Laboratories by 8.0% in the 3rd quarter. Invesco Ltd. now owns 343,462 shares of the medical research company’s stock valued at $123,114,000 after purchasing an additional 25,562 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $116,036,000. Finally, Thompson Siegel & Walmsley LLC increased its holdings in shares of Bio-Rad Laboratories by 6.3% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 312,583 shares of the medical research company’s stock worth $112,046,000 after buying an additional 18,419 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Insider Activity at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the sale, the executive vice president now owns 6,942 shares in the company, valued at approximately $2,332,512. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 17.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

BIO has been the topic of a number of recent analyst reports. Royal Bank of Canada decreased their price objective on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. UBS Group upped their price target on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a research note on Friday, February 16th. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Finally, Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their target price for the company from $400.00 to $365.00 in a research report on Wednesday, April 3rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and an average price target of $468.00.

Bio-Rad Laboratories Stock Up 0.4 %

Shares of NYSE:BIO opened at $276.96 on Tuesday. The firm has a market capitalization of $7.90 billion, a PE ratio of -12.89 and a beta of 0.87. Bio-Rad Laboratories, Inc. has a 1 year low of $261.59 and a 1 year high of $473.50. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34. The firm’s 50-day moving average is $323.67 and its two-hundred day moving average is $316.47.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The company had revenue of $681.18 million for the quarter, compared to analyst estimates of $685.00 million. During the same period in the prior year, the business earned $3.31 EPS. The firm’s quarterly revenue was down 6.7% on a year-over-year basis. Analysts predict that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.